Vir Biotechnology Inc (VIR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vir Biotechnology Inc (VIR) Competitors
The companies most similar to Vir Biotechnology are Vera Therapeutics (VERA), Legend Biotech (LEGN) and Novavax (NVAX). By market cap, Vir Biotechnology ranks 7th of the 13 companies on this page; Viridian Therapeutics (VRDN) is the largest at $3.51B. The median P/E of the 3 companies with a P/E is 89.8x.
Peer Comparison
VIR's revenue growth of 19582.0% is above the peer median of -0.8%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Vir Biotechnology (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Novavax Inc (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Innoviva Inc (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Viridian Therapeutics Inc (VRDN) | $3.51B | N/A | 128.5x | 0.0% | -41.8% | -63.5% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Vericel Corp Ord (VCEL) | $2.91B | 89.8x | 9.1x | 10.3% | N/A | 26.5% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Forte Biosciences Inc (FBRX) | $1.63B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $1.77B | 89.8x | 15.0x | 0.0% | -66.0% | -0.8% | 0.00% |
Similar Companies
These are the 12 companies most similar to Vir Biotechnology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Novavax Inc (NVAX) | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases... | NVAX competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Innoviva Inc (INVA) | Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California. | INVA competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
| Viridian Therapeutics Inc (VRDN) | Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. | VRDN competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Vericel Corp Ord (VCEL) | Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures... | VCEL competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Forte Biosciences Inc (FBRX) | Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California. |
Frequently Asked Questions About VIR
Who are Vir Biotechnology's main competitors?
The companies most similar to Vir Biotechnology include Vera Therapeutics (VERA), Legend Biotech (LEGN), Novavax (NVAX), Beam Therapeutics (BEAM) and Innoviva (INVA), listed from the closest match.
Who is Vir Biotechnology's biggest competitor?
Viridian Therapeutics (VRDN) is the largest of the similar companies at $3.51B; Vera Therapeutics (VERA) is the closest match by business profile, size, sector and industry.
How does VIR stock compare with its competitors?
VIR's P/S is 5.4x against a peer median of 15.0x; its net margin is -61.0% against a peer median of 0.0%.
Which of Vir Biotechnology's competitors pays a higher dividend?
Vir Biotechnology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Vir Biotechnology bigger than its competitors?
No. Vir Biotechnology is 7th by market cap among the 13 companies on this page; the largest is Viridian Therapeutics (VRDN) at $3.51B.
VIR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts